IL6 and breast carcinoma: As a steroid hormone with anti-inflammatory effects, estrogen downregulates the levels of IL-6 and gp130 levels in osteoblasts and breast cancer cells, thereby affecting the downstream IL-6/gp130 signaling pathway [39, 40].